Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

April 7, 2022

Study Completion Date

October 17, 2024

Conditions
Desmoid TumorAggressive Fibromatosis
Interventions
DRUG

Nirogacestat oral tablet

Nirogacestat tablet

DRUG

Placebo Oral Tablet

Sugar pill manufactured to mimic nirogacestat 50 mg tablet

Trial Locations (52)

1000

Institut Jules Bordet-Medical Oncology, Brussels

1066

The Netherlands Cancer Institute, Amsterdam

1200

Cliniques Universitaires Saint-Luc, Institut Roi Albert II, Brussels

3000

UZ Leuven, Leuven

9000

UZ Gent, Ghent

10032

Columbia University Medical Center, New York

10060

Istituto di Candiolo IRCCS Oncologia Medica, Candiolo

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Northwell Health, Lake Success

13125

Helios Klinikum Berlin-Buch, Berlin

15232

UPMC Hillman Cancer Center, Pittsburgh

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

20010

Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C.

20133

Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

21287

Johns Hopkins Hospital, Baltimore

23333

Leiden University Medical Center (LUMC), Leiden

27710

DUMC/Duke Cancer Center, Durham

32224

Mayo Clinic Florida, Jacksonville

33136

Sylvester Comprehensive Cancer Center, Miami

37232

Henry-Joyce Cancer Clinic, Nashville

40136

IRCCS Istituto Ortopedico Rizzoli, Bologna

43210

James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

University of Michigan, Ann Arbor

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

53792

University of Wisconsin Clinical Science Center, Madison

55905

Mayo Clinic Rochester, Rochester

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University School of Medicine, St Louis

72202

Arkansas Children's Hospital, Little Rock

75390

UT Southwestern Medical Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Hospital-Anschutz Cancer Pavilion (ACP), Aurora

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

90095

Ronald Regan UCLA Medical Center, Los Angeles

90403

Sarcoma Oncology Research Center, Santa Monica

94158

UCSF Mission Bay, San Francisco

94304

Stanford Cancer Center, Palo Alto

97201

Oregon Health & Science University-Center for Health & Healing, Portland

98109

Seattle Cancer Care Alliance, Seattle

06510

Smilow Cancer Hospital at Yale-New Haven, New Haven

02114

Massachusetts General Hosptial (MGH), Boston

02215

Dana-Farber Cancer Institute (DFCI), Boston

M5G2M9

Princess Margaret Cancer Centre, Toronto

H4A3JI

McGill University Health Centre, Montreal

D-68167

Universitätsmedizin Mannheim, Mannheim

00128

Policlinico Unvrsitario Campus Bio-Medico, Roma

6525GA

Radboud University Medical Centre, Nijmegen

NW12PG

Department of Oncology, University College of London Hospital, London

SW36JJ

The Royal Marsden NHS Foundation Trust, London

All Listed Sponsors
lead

SpringWorks Therapeutics, Inc.

INDUSTRY

NCT03785964 - Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Biotech Hunter | Biotech Hunter